[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

1-877-240-9479

Email address

information.center@astrazeneca.com

Condition

Chronic Obstructive Pulmonary Disease (COPD)

Treatment type

Interventional

Investigational product

Tezepelumab

Phase

Phase 2

Sponsor

AstraZeneca

ClinicalTrials.gov identifier

NCT04039113

Study number

D5241C00001

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. LAMA) throughout the year prior to enrollment. The dose of ICS should be stable for 3 months prior to enrollment.
Exclusion criteria

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site